{"id":475,"date":"2026-02-11T12:03:19","date_gmt":"2026-02-11T12:03:19","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/475\/"},"modified":"2026-02-11T12:03:19","modified_gmt":"2026-02-11T12:03:19","slug":"roche-reports-positive-results-for-experimental-obesity-drug","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/475\/","title":{"rendered":"Roche reports positive results for experimental obesity drug"},"content":{"rendered":"

\"Roche<\/p>\n

Roche aims to challenge major players Novo Nordisk and Eli Lilly for a place in the fast-growing market. <\/p>\n

Keystone-SDA <\/p>\n

Swiss pharma giant Roche said on Tuesday that a phase II clinical trial of its experimental obesity drug CT-388 had given positive results.\n<\/p>\n

Listen to the article <\/p>\n

Listening the article <\/p>\n

Toggle language selector <\/p>\n

English (US) <\/p>\n

English (British) <\/p>\n

Generated with artificial intelligence. <\/p>\n

This content was published on <\/p>\n

January 27, 2026 – 08:51\n<\/p>\n

+Get the most important news from Switzerland in your inbox<\/a><\/p>\n

In the study participants who received the active ingredient CT-388 once a week for 48 weeks lost over 20% of their body weight on average, Roche said in a press release on Monday.<\/p>\n

The higher the dose administered, the greater the weight loss. The effects were particularly clear at the highest dose tested. Almost all participants lost at least 5% of their body weight, around half even lost more than 20% and a quarter lost over 30%.<\/p>\n

Drug well tolerated<\/p>\n

According to Roche, the metabolism also benefited. Blood glucose levels normalised in almost three-quarters of the study participants with a preliminary stage of diabetes, significantly more than in the comparison group without the active ingredient.<\/p>\n

\n More<\/p>\n

\"Companies<\/p>\n

More <\/p>\n

Healthcare innovation\n <\/p>\n

The race to launch a pill for weight loss <\/p>\n

\n

This content was published on <\/p>\n

Oct 30, 2025 <\/p>\n

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine. <\/p>\n

<\/p>\n

Read more: The race to launch a pill for weight loss
\n <\/a><\/p>\n

The drug was well tolerated overall. The most common side effects related to the gastrointestinal tract and were mostly mild to moderate. Only a few participants discontinued treatment due to side effects.<\/p>\n

Roche views the results as an important step in the development of new treatments for obesity, one of the biggest causes of chronic disease worldwide. Based on the published data, the Basel-based company is now planning to start large-scale pivotal Phase III trials to further evaluate the efficacy and safety of the drug.<\/p>\n

\n More<\/p>\n

\"obese\"<\/p>\n

More <\/p>\n

Rising Swiss obesity levels: can new fat loss drugs like Ozempic and Wegovy help?\u00a0 <\/p>\n

\n

This content was published on <\/p>\n

May 31, 2024 <\/p>\n

The proportion of obese people in Switzerland has more than doubled over the last three decades. <\/p>\n

<\/p>\n

Read more: Rising Swiss obesity levels: can new fat loss drugs like Ozempic and Wegovy help?\u00a0
\n <\/a><\/p>\n

Adapted from German by AI\/sb<\/p>\n

How we work\u00a0 <\/p>\n

We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.\u00a0\u00a0<\/p>\n

Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.<\/p>\n

If you have any questions about how we work, write to us at english@swissinfo.ch<\/a><\/p>\n

Articles in this story <\/p>\n","protected":false},"excerpt":{"rendered":"Roche aims to challenge major players Novo Nordisk and Eli Lilly for a place in the fast-growing market.…\n","protected":false},"author":2,"featured_media":476,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[101,596,595,300,100,304,103,597,134,102],"class_list":{"0":"post-475","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-article","9":"tag-beat-healthcare-innovation","10":"tag-beat-new-treatments","11":"tag-beat-pharma-supply-chains","12":"tag-latest-news","13":"tag-pharmaceutical","14":"tag-production-type-deepl-autotranslation","15":"tag-research-and-development","16":"tag-roche","17":"tag-sda-ready-to-publish"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=475"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/476"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}